Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for lichen planus pilot study
2021-006031-25Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lichen planus (LP) and oral lichen planus (OLP) comparing Upadacitinib with Placebo (2 arms). Primary endpoint: Clinical response in mucosal disease at week 12. Started Apr 2022; status: completed.
02
Drugs
upadacitinib
03
Conditions
lichen planus (LP)oral lichen planus (OLP)
Beyond the preview
Go deeper on 2021-006031-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006031-25.